Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer
- Address
- lock Available on a paid plan
Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer - Advanced Oncology and Cardiovascular Research
The Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer is a comprehensive medical research facility with a strong focus on oncology clinical trials and cardiovascular disease research. The center demonstrates particular expertise in non-small cell lung cancer therapeutics, investigating multiple immunotherapy combinations and targeted therapies across various disease stages, from early-stage resectable disease to advanced metastatic presentations.
- Non-small cell lung cancer: immunotherapy trials with pembrolizumab, atezolizumab, cemiplimab, and novel checkpoint inhibitors in combination with chemotherapy and targeted agents
- Head and neck cancer: evaluation of avelumab-cetuximab-radiotherapy combinations and novel treatment approaches for locally advanced squamous cell carcinomas
- Cardiovascular conditions: heart failure management with novel drug combinations, hypertension treatment optimization, and cardiac arrest management protocols
- Cancer-associated thromboembolism: anticoagulation strategies and bleeding risk management in oncology patients
Beyond oncology, the center conducts research in inflammatory bowel diseases including Crohn's disease and ulcerative colitis, investigating biologic therapies and treatment optimization strategies. The facility also participates in studies addressing venous thromboembolism, pleural mesothelioma, prostate cancer, and chronic lymphocytic leukemia, demonstrating a diverse research portfolio that spans multiple therapeutic areas. Their participation in phase II and III trials reflects their capacity to conduct both early efficacy studies and large-scale confirmatory research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 13 therapeutic areas and 15 of 146 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 131 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 29 by active trials.
lock +28 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +15 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer
lock Showing 1 of 71 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 146 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 13 | Unknown | 2020-12-18 | 2026-05-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.